Is BIB a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

263 people get BIB articles and Market Currents by email alert.

Get email alerts on BIB »

HEADLINES:

Best And Worst ETFs And Mutual Funds: Health Care Sector
David Trainer • Thu, Apr 25 • 5 Comments
Playing To The Strengths Of Biotech
Richard Cox • Sat, Apr 13 • 5 Comments
Biotech Disaster 101: When The Market Takes A Dive, Biotechs Sink To The Bottom
Spencer Knight • Wed, Jun 6, 2012 • 1 Comment
Greece Is To Wall Street Like A Flame Is To A Moth
Daniel Sckolnik • Tue, Feb 14, 2012 • 5 Comments
5 Leveraged ETFs Delivering Big Gains
Michael Johnston • Tue, Jan 31, 2012 • 1 Comment
A Strategy For Shorting Leveraged ETF Pairs
Eric Falkenstein • Mon, Oct 31, 2011 • 5 Comments
Best In Class Healthcare And Biotech ETFs
Barchart's ETF Recommendations • Tue, Sep 20, 2011
Biotech And Pharma M&A Advances In H1 2011
The Burrill Report • Mon, Aug 22, 2011
Biotechs: Revenues Rise, But So Do Cutbacks in R&D
Pharmalot • Mon, Aug 1, 2011
Big Pharma's Cutbacks Are Small Biotechs' Opportunity
The Burrill Report • Fri, Jul 29, 2011 • 2 Comments
ETF Deathwatch: Count Increases to 155
Ron Rowland • Mon, Jul 11, 2011
ETF Kings: Best Performers From First Half of 2011
Michael Johnston • Fri, Jul 8, 2011 • 1 Comment
Growth in U.S. Drug Sales Slows
The Burrill Report • Thu, Apr 21, 2011 • 1 Comment
Why Phase II Trials Are the Best Time for Biotech Investing
Marc Lichtenfeld • Thu, Apr 14, 2011 • 1 Comment
Jobs Data Lift ETFs
Tom Lydon • Wed, Mar 30, 2011
How to Maneuver the Biotech Sector
Spencer Knight • Tue, Mar 29, 2011 • 2 Comments
How Will 'Me Too' Drug Regs Affect the Biotech Industry?
Pharmalot • Wed, Feb 16, 2011 • 1 Comment
Dissipate the Risk in Biotechnology With ETFs
Tom Lydon • Wed, Jan 19, 2011
13 Predictions for Biotech in 2011
The Burrill Report • Sun, Jan 2, 2011 • 1 Comment
Play the Booming Biotech Sector With These Four ETFs
Tom Lydon • Wed, Dec 22, 2010 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Adding Leverage to an Already Volatile Sector: ProShares Launches 2x Long, Short Biotech ETFs
Invest With An Edge • Fri, Apr 9, 2010 • 1 Comment

Best And Worst ETFs And Mutual Funds: Health Care Sector
David Trainer • Thu, Apr 25 • 5 Comments
Playing To The Strengths Of Biotech
Richard Cox • Sat, Apr 13 • 5 Comments
Biotech Disaster 101: When The Market Takes A Dive, Biotechs Sink To The Bottom
Spencer Knight • Wed, Jun 6, 2012 • 1 Comment
Greece Is To Wall Street Like A Flame Is To A Moth
Daniel Sckolnik • Tue, Feb 14, 2012 • 5 Comments
5 Leveraged ETFs Delivering Big Gains
Michael Johnston • Tue, Jan 31, 2012 • 1 Comment
A Strategy For Shorting Leveraged ETF Pairs
Eric Falkenstein • Mon, Oct 31, 2011 • 5 Comments
Best In Class Healthcare And Biotech ETFs
Barchart's ETF Recommendations • Tue, Sep 20, 2011
Biotech And Pharma M&A Advances In H1 2011
The Burrill Report • Mon, Aug 22, 2011
Biotechs: Revenues Rise, But So Do Cutbacks in R&D
Pharmalot • Mon, Aug 1, 2011
Big Pharma's Cutbacks Are Small Biotechs' Opportunity
The Burrill Report • Fri, Jul 29, 2011 • 2 Comments
ETF Deathwatch: Count Increases to 155
Ron Rowland • Mon, Jul 11, 2011
ETF Kings: Best Performers From First Half of 2011
Michael Johnston • Fri, Jul 8, 2011 • 1 Comment
Growth in U.S. Drug Sales Slows
The Burrill Report • Thu, Apr 21, 2011 • 1 Comment
Why Phase II Trials Are the Best Time for Biotech Investing
Marc Lichtenfeld • Thu, Apr 14, 2011 • 1 Comment
Jobs Data Lift ETFs
Tom Lydon • Wed, Mar 30, 2011
How to Maneuver the Biotech Sector
Spencer Knight • Tue, Mar 29, 2011 • 2 Comments
How Will 'Me Too' Drug Regs Affect the Biotech Industry?
Pharmalot • Wed, Feb 16, 2011 • 1 Comment
Dissipate the Risk in Biotechnology With ETFs
Tom Lydon • Wed, Jan 19, 2011
13 Predictions for Biotech in 2011
The Burrill Report • Sun, Jan 2, 2011 • 1 Comment
Play the Booming Biotech Sector With These Four ETFs
Tom Lydon • Wed, Dec 22, 2010 • 1 Comment

There are no Transcripts on BIB.

What's on Sanofi's shopping list?

at MarketWatch.com (Mar 6, 2012)
Chuck Jaffe: How to buy stocks high and sell them low

at MarketWatch.com (Jul 1, 2011)

BIB vs. ETF Alternatives

BIB Description

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology® Index.
See more details on sponsor's website

Sector: Healthcare

Country: United States

Key Info

In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
Asset Class Performance: Sectors

All
| Earnings
| Dividends
| M&A
| On the move

Monday, September 24, 2012, 3:56 PM ProShares sets splits and reverse splits on 11 of its levered ETFs to try and bring the share prices back to levels more palatable to traders. Among those affected is a favorite of pain-seekers, the double-levered short 20+ Year Treasury fund (TBT), which will see a 1-for-4 reverse split on Oct. 4. 2 Comments
Monday, March 12, 2012, 12:07 PM Shares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector. Comment! [On the Move, Healthcare, Quick Ideas]
Wednesday, September 7, 2011, 11:36 AM The biotech industry looks ripe for more gains after posting a second consecutive year of profits and seeing M&A activity heat up, says Karvy Global Services. Crunching the numbers reveals 8 stocks with implied upside potential based on quarterly results and analyst recommendations. Picks: HITK, CELG, DNDN, WX, TEVA, ILMN, CRL, BIIB. Comment! [Quick Ideas]
Thursday, August 4, 2011, 4:05 PM Dendreon (DNDN -67.4%) takes down an entire industry, with the Amex Biotech index falling an astonishing 10.4%. "Biotech risk takers burned on this one might be less risk tolerant going forward," one analyst explains. "The biotech group does work like that, especially for product failures." IBB -7.9%. XBI -9.8%. Comment! [Healthcare, On the Move, Top Stories]
Monday, March 7, 2011, 7:43 AM Sanofi (SNY) extends its offer for the outstanding shares of Genzyme (GENZ) to April 1 from March 16. Meanwhile, other biotech firms focused on rare diseases say the Sanofi-Genzyme deal puts many peers into play as takeover targets. Comment!
Saturday, October 30, 2010, 4:58 PM In a major policy reversal, the DoJ filed an amicus brief late yesterday saying human DNA and other genes shouldn't be eligible for patents. It's unclear whether the Patent Office will adopt the position, which could potentially force some biotech firms to change the way they develop drugs.
Comment!

iadops40
#biotech getting stuffed here BIB
10/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The_American
GSK DNDN TNGN.OB CTIC STEM should ALL be looked at into the BIB space and PFE MRK GSK should be looking into much more MDT also looking AMRS X
4/21/12
Reply (6)

• !Report Abuse
View all 6 replies
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
Add a reply...

140 characters

The_American
SDY PID DVY VIG DTD PFM DES in comparison to some great asset backed REITs & all not created equal TWO ARR NLY AGNC then M&A in BIB GDX REE
1/10/12
Reply (3)

• !Report Abuse
View all 3 replies
The_American: Watch SLV SIVR PSLV SIL There was an accumulation period. Short & Long term SLV probably most undervalued metal of them ALL Very TVIX HL PAL
1/22/12
• !Report Abuse
DAG1996: will do thanks
1/22/12
• !Report Abuse
Add a reply...

140 characters

Jim Van Meerten
BIB - 100% Barchart technical buy signal - 10 new highs and up 9.96% in the last month - Relative strength Index 70.69%
1/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

candlestickpicks
BIB completed a Bullish Engulfing candlestick pattern on 8/20/2010. Look for an upward price movement on 8/23/2010
8/22/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

The_American
GSK DNDN TNGN.OB CTIC STEM should ALL be looked at into the BIB space and PFE MRK GSK should be looking into much more MDT also looking AMRS X
4/21/12
Reply (6)

• !Report Abuse
View all 6 replies
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
Add a reply...

140 characters

The_American
SDY PID DVY VIG DTD PFM DES in comparison to some great asset backed REITs & all not created equal TWO ARR NLY AGNC then M&A in BIB GDX REE
1/10/12
Reply (3)

• !Report Abuse
View all 3 replies
The_American: Watch SLV SIVR PSLV SIL There was an accumulation period. Short & Long term SLV probably most undervalued metal of them ALL Very TVIX HL PAL
1/22/12
• !Report Abuse
DAG1996: will do thanks
1/22/12
• !Report Abuse
Add a reply...

140 characters

BIB ProShares Ultra Nasdaq Biotechnology ETF

BIB

ProShares Ultra Nasdaq Biotechnology ETF